Ostarine would be the closest SARM to becoming approved in medicine and is also currently in phase II clinical trials. Like SARMs in general, MK-2866 targets androgen receptors on the selective basis and avoids producing the kinds of damaging side effects involved with substances like testosterone, human growth hormone, or https://popen814jlo0.anchor-blog.com/profile